Specificity of CTL generated with BCR-ABL peptide KQSSKALQR (% positive wells against target cells)
| Patient . | Autologous lymphoblasts without peptide . | Autologous lymphoblasts with peptide . | Matched lymphoblasts without peptide . | Matched lymphoblasts with peptide . | Autologous CML cells . | Matched CML cells . | Mismatched CML cells . |
|---|---|---|---|---|---|---|---|
| CML patients | |||||||
| HLA-A∗0301 positive | |||||||
| 1 | 6 | 44 | 4 | 33 | 58 | 36 | 6 |
| 2 | 4 | 51 | 2 | 27 | 27 | — | — |
| 3 | 5 | 15 | 7 | 10 | 27 | — | 1 |
| 4 | 1 | 20 | 6 | 21 | — | — | 5 |
| 5 | 5 | 30 | 7 | 19 | — | 26 | 6 |
| HLA-A∗0301 negative | |||||||
| 7 | 1 | 4 | 1 | 11 | — | 1 | — |
| 8 | 5 | 3 | 4 | 7 | — | 6 | 7 |
| Healthy subjects | |||||||
| 10 | 0 | 33 | 5 | 20 | N/A | 39 | 5 |
| 11 | 6 | 32 | 5 | 19 | N/A | 42 | 8 |
| Patient . | Autologous lymphoblasts without peptide . | Autologous lymphoblasts with peptide . | Matched lymphoblasts without peptide . | Matched lymphoblasts with peptide . | Autologous CML cells . | Matched CML cells . | Mismatched CML cells . |
|---|---|---|---|---|---|---|---|
| CML patients | |||||||
| HLA-A∗0301 positive | |||||||
| 1 | 6 | 44 | 4 | 33 | 58 | 36 | 6 |
| 2 | 4 | 51 | 2 | 27 | 27 | — | — |
| 3 | 5 | 15 | 7 | 10 | 27 | — | 1 |
| 4 | 1 | 20 | 6 | 21 | — | — | 5 |
| 5 | 5 | 30 | 7 | 19 | — | 26 | 6 |
| HLA-A∗0301 negative | |||||||
| 7 | 1 | 4 | 1 | 11 | — | 1 | — |
| 8 | 5 | 3 | 4 | 7 | — | 6 | 7 |
| Healthy subjects | |||||||
| 10 | 0 | 33 | 5 | 20 | N/A | 39 | 5 |
| 11 | 6 | 32 | 5 | 19 | N/A | 42 | 8 |
Data are expressed as the percentage of wells with51Cr release > 3 SDs above the mean background51Cr release.16 Percentages in bold were significantly different (P < .001) from their respective control (Fisher exact test). CTL, cytotoxic T lymphocyte; CML, chronic myeloid leukemia; —, not done because of insufficient effector cells; N/A, not applicable.